



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2013	2012	% Change			2013	2012	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER SEGMENT <sup>(2)(4)</sup></b>										
<b>BABY CARE</b>										
US	\$ 106	106	0.0%	0.0%	-	\$ 209	205	2.0%	2.0%	-
Intl	480	472	1.7%	3.8%	-2.1%	941	913	3.1%	5.7%	-2.6%
WW	586	578	1.4%	3.1%	-1.7%	1,150	1,118	2.9%	5.0%	-2.1%
<b>ORAL CARE</b>										
US	149	159	-6.3%	-6.3%	-	307	314	-2.2%	-2.2%	-
Intl	257	249	3.2%	4.3%	-1.1%	502	481	4.4%	5.8%	-1.4%
WW	406	408	-0.5%	0.2%	-0.7%	809	795	1.8%	2.6%	-0.8%
<b>OTC <sup>(3)</sup></b>										
US	290	247	17.4%	17.4%	-	644	538	19.7%	19.7%	-
Intl	641	636	0.8%	0.9%	-0.1%	1,330	1,296	2.6%	3.0%	-0.4%
WW	931	883	5.4%	5.4%	0.0%	1,974	1,834	7.6%	7.9%	-0.3%
<b>SKIN CARE</b>										
US	463	471	-1.7%	-1.7%	-	916	924	-0.9%	-0.9%	-
Intl	445	442	0.7%	1.0%	-0.3%	894	896	-0.2%	0.3%	-0.5%
WW	908	913	-0.5%	-0.4%	-0.1%	1,810	1,820	-0.5%	-0.3%	-0.2%
<b>WOMEN'S HEALTH</b>										
US	84	80	5.0%	5.0%	-	165	173	-4.6%	-4.6%	-
Intl	327	322	1.6%	3.4%	-1.8%	647	638	1.4%	4.1%	-2.7%
WW	411	402	2.2%	3.6%	-1.4%	812	811	0.1%	2.2%	-2.1%
<b>WOUND CARE/OTHER <sup>(3)</sup></b>										
US	234	250	-6.4%	-6.4%	-	433	475	-8.8%	-8.8%	-
Intl	182	185	-1.6%	-1.4%	-0.2%	345	361	-4.4%	-4.0%	-0.4%
WW	416	435	-4.4%	-4.3%	-0.1%	778	836	-6.9%	-6.7%	-0.2%
<b>TOTAL CONSUMER</b>										
US	1,326	1,313	1.0%	1.0%	-	2,674	2,629	1.7%	1.7%	-
Intl	2,332	2,306	1.1%	2.0%	-0.9%	4,659	4,585	1.6%	2.9%	-1.3%
WW	\$ 3,658	3,619	1.1%	1.7%	-0.6%	\$ 7,333	7,214	1.6%	2.4%	-0.8%

See footnotes at end of schedule

Supplemental Sales Information

	2012					2013
	Q1	Q2	Q3	Q4	FY	Q1
<b>OTC</b>						
US	291	247	263	273	1,074	354
Intl	660	636	653	743	2,692	689
WW	951	883	916	1,016	3,766	1,043
<b>WOUND CARE/OTHER</b>						
US	225	250	214	195	884	199
Intl	176	185	163	152	676	163
WW	401	435	377	347	1,560	362

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>SECOND QUARTER</b>					<b>SIX MONTHS</b>				
	<b>2013</b>	<b>2012</b>	<b>% Change</b>			<b>2013</b>	<b>2012</b>	<b>% Change</b>		
			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>
<b>PHARMACEUTICAL SEGMENT <sup>(2) (4)</sup></b>										
<b>IMMUNOLOGY</b>										
US	\$ 1,578	1,471	7.3%	7.3%	-	\$ 3,217	2,924	10.0%	10.0%	-
Intl	663	448	48.0%	51.5%	-3.5%	1,228	890	38.0%	40.9%	-2.9%
WW	2,241	1,919	16.8%	17.6%	-0.8%	4,445	3,814	16.5%	17.2%	-0.7%
<b>REMICADE</b>										
US	926	890	4.0%	4.0%	-	1,896	1,772	7.0%	7.0%	-
US Exports <sup>(5)</sup>	332	366	-9.3%	-9.3%	-	681	744	-8.5%	-8.5%	-
Intl	414	267	55.1%	58.2%	-3.1%	695	528	31.6%	34.0%	-2.4%
WW	1,672	1,523	9.8%	10.3%	-0.5%	3,272	3,044	7.5%	7.9%	-0.4%
<b>SIMPONI</b>										
US	87	63	38.1%	38.1%	-	181	127	42.5%	42.5%	-
Intl	88	62	41.9%	48.3%	-6.4%	231	114	*	*	-4.5%
WW	175	125	40.0%	43.2%	-3.2%	412	241	71.0%	73.5%	-2.5%
<b>STELARA</b>										
US	233	152	53.3%	53.3%	-	459	281	63.3%	63.3%	-
Intl	138	96	43.8%	45.4%	-1.6%	258	188	37.2%	38.4%	-1.2%
WW	371	248	49.6%	50.2%	-0.6%	717	469	52.9%	53.4%	-0.5%
<b>OTHER IMMUNOLOGY</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	23	23	0.0%	1.1%	-1.1%	44	60	-26.7%	-26.1%	-0.6%
WW	23	23	0.0%	1.1%	-1.1%	44	60	-26.7%	-26.1%	-0.6%
<b>INFECTIOUS DISEASES</b>										
US	259	237	9.3%	9.3%	-	497	479	3.8%	3.8%	-
Intl	711	551	29.0%	30.2%	-1.2%	1,288	1,064	21.1%	22.2%	-1.1%
WW	970	788	23.1%	23.9%	-0.8%	1,785	1,543	15.7%	16.5%	-0.8%
<b>INCIVO</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	172	102	68.6%	71.8%	-3.2%	334	234	42.7%	45.4%	-2.7%
WW	172	102	68.6%	71.8%	-3.2%	334	234	42.7%	45.4%	-2.7%
<b>INTELENCE</b>										
US	44	42	4.8%	4.8%	-	91	85	7.1%	7.1%	-
Intl	59	49	20.4%	21.0%	-0.6%	101	86	17.4%	18.0%	-0.6%
WW	103	91	13.2%	13.5%	-0.3%	192	171	12.3%	12.6%	-0.3%
<b>PREZISTA</b>										
US	196	166	18.1%	18.1%	-	363	326	11.3%	11.3%	-
Intl	239	207	15.5%	16.0%	-0.5%	439	371	18.3%	18.7%	-0.4%
WW	435	373	16.6%	16.9%	-0.3%	802	697	15.1%	15.3%	-0.2%
<b>OTHER INFECTIOUS DISEASES</b>										
US	19	29	-34.5%	-34.5%	-	43	68	-36.8%	-36.8%	-
Intl	241	193	24.9%	25.8%	-0.9%	414	373	11.0%	11.9%	-0.9%
WW	260	222	17.1%	17.9%	-0.8%	457	441	3.6%	4.3%	-0.7%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	SECOND QUARTER					SIX MONTHS					
	2013	2012	% Change			2013	2012	% Change			
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency	
<b>NEUROSCIENCE</b>											
US	626	658	-4.9%	-4.9%	-	1,372	1,332	3.0%	3.0%	-	
Intl	1,054	1,056	-0.2%	3.8%	-4.0%	2,052	2,029	1.1%	4.6%	-3.5%	
WW	1,680	1,714	-2.0%	0.4%	-2.4%	3,424	3,361	1.9%	4.0%	-2.1%	
<b>CONCERTA/METHYLPHENIDATE</b>											
US	85	146	-41.8%	-41.8%	-	224	343	-34.7%	-34.7%	-	
Intl	130	122	6.6%	8.9%	-2.3%	247	233	6.0%	7.9%	-1.9%	
WW	215	268	-19.8%	-18.7%	-1.1%	471	576	-18.2%	-17.4%	-0.8%	
<b>INVEGA</b>											
US	76	76	0.0%	0.0%	-	147	145	1.4%	1.4%	-	
Intl	74	66	12.1%	18.3%	-6.2%	135	118	14.4%	19.9%	-5.5%	
WW	150	142	5.6%	8.4%	-2.8%	282	263	7.2%	9.7%	-2.5%	
<b>INVEGA SUSTENNA/ XEPLION</b>											
US	158	120	31.7%	31.7%	-	322	220	46.4%	46.4%	-	
Intl	132	75	76.0%	75.0%	1.0%	252	136	85.3%	84.4%	0.9%	
WW	290	195	48.7%	48.3%	0.4%	574	356	61.2%	60.9%	0.3%	
<b>RISPERDAL CONSTA</b>											
US	107	110	-2.7%	-2.7%	-	213	223	-4.5%	-4.5%	-	
Intl	229	245	-6.5%	-3.7%	-2.8%	458	493	-7.1%	-4.9%	-2.2%	
WW	336	355	-5.4%	-3.5%	-1.9%	671	716	-6.3%	-4.8%	-1.5%	
<b>OTHER NEUROSCIENCE</b>											
US	200	206	-2.9%	-2.9%	-	466	401	16.2%	16.2%	-	
Intl	489	548	-10.8%	-5.5%	-5.3%	960	1,049	-8.5%	-3.7%	-4.8%	
WW	689	754	-8.6%	-4.8%	-3.8%	1,426	1,450	-1.7%	1.8%	-3.5%	
<b>ONCOLOGY</b>											
US	206	119	73.1%	73.1%	-	405	226	79.2%	79.2%	-	
Intl	679	467	45.4%	48.1%	-2.7%	1,274	956	33.3%	35.8%	-2.5%	
WW	885	586	51.0%	53.2%	-2.2%	1,679	1,182	42.0%	44.0%	-2.0%	
<b>VELCADE</b>											
US	-	-	-	-	-	-	-	-	-	-	
Intl	379	318	19.2%	22.7%	-3.5%	732	671	9.1%	12.1%	-3.0%	
WW	379	318	19.2%	22.7%	-3.5%	732	671	9.1%	12.1%	-3.0%	
<b>ZYTIGA</b>											
US	174	113	54.0%	54.0%	-	335	213	57.3%	57.3%	-	
Intl	221	119	85.7%	85.2%	0.5%	404	219	84.5%	84.4%	0.1%	
WW	395	232	70.3%	70.0%	0.3%	739	432	71.1%	71.1%	0.0%	
<b>OTHER ONCOLOGY</b>											
US	32	6	*	*	-	70	13	*	*	-	
Intl	79	30	*	*	-7.4%	138	66	*	*	-6.0%	
WW	111	36	*	*	-6.1%	208	79	*	*	-5.0%	

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>SECOND QUARTER</b>					<b>SIX MONTHS</b>				
	<b>2013</b>	<b>2012</b>	<b>% Change</b>			<b>2013</b>	<b>2012</b>	<b>% Change</b>		
			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>
<b>TOTAL OTHER</b>										
US	708	609	16.3%	16.3%	-	1,357	1,159	17.1%	17.1%	-
Intl	541	675	-19.9%	-19.9%	0.0%	1,103	1,365	-19.2%	-18.6%	-0.6%
WW	1,249	1,284	-2.7%	-2.7%	0.0%	2,460	2,524	-2.5%	-2.2%	-0.3%
<b>ACIPHEX/PARIET</b>										
US	97	104	-6.7%	-6.7%	-	200	200	0.0%	0.0%	-
Intl	59	128	-53.9%	-54.0%	0.1%	108	254	-57.5%	-57.3%	-0.2%
WW	156	232	-32.8%	-32.8%	0.0%	308	454	-32.2%	-32.1%	-0.1%
<b>PROCRIPT/EPREX</b>										
US	190	232	-18.1%	-18.1%	-	423	436	-3.0%	-3.0%	-
Intl	145	169	-14.2%	-14.6%	0.4%	290	341	-15.0%	-15.3%	0.3%
WW	335	401	-16.5%	-16.7%	0.2%	713	777	-8.2%	-8.3%	0.1%
<b>XARELTO</b>										
US	189	49	*	*	-	347	76	*	*	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	189	49	*	*	-	347	76	*	*	-
<b>OTHER</b>										
US	232	224	3.6%	3.6%	-	387	447	-13.4%	-13.4%	-
Intl	337	378	-10.8%	-10.5%	-0.3%	705	770	-8.4%	-7.4%	-1.0%
WW	569	602	-5.5%	-5.3%	-0.2%	1,092	1,217	-10.3%	-9.7%	-0.6%
<b>TOTAL PHARMACEUTICAL</b>										
US	3,377	3,094	9.1%	9.1%	-	6,848	6,120	11.9%	11.9%	-
Intl	3,648	3,197	14.1%	16.5%	-2.4%	6,945	6,304	10.2%	12.4%	-2.2%
WW	\$ 7,025	\$ 6,291	11.7%	12.9%	-1.2%	\$ 13,793	\$ 12,424	11.0%	12.1%	-1.1%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	SECOND QUARTER					SIX MONTHS				
	2013	2012	% Change			2013	2012	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>MEDICAL DEVICES AND DIAGNOSTICS <sup>(2)</sup></b>										
<u>CARDIOVASCULAR CARE</u>										
US	\$ 204	195	4.6%	4.6%	-	\$ 402	371	8.4%	8.4%	-
Intl	325	309	5.2%	9.6%	-4.4%	640	615	4.1%	8.0%	-3.9%
WW	529	504	5.0%	7.7%	-2.7%	1,042	986	5.7%	8.1%	-2.4%
<u>DIABETES CARE</u>										
US	259	337	-23.1%	-23.1%	-	542	689	-21.3%	-21.3%	-
Intl	330	336	-1.8%	-0.5%	-1.3%	647	654	-1.1%	0.2%	-1.3%
WW	589	673	-12.5%	-11.8%	-0.7%	1,189	1,343	-11.5%	-10.9%	-0.6%
<u>DIAGNOSTICS</u>										
US	241	258	-6.6%	-6.6%	-	489	511	-4.3%	-4.3%	-
Intl	242	256	-5.5%	-1.5%	-4.0%	471	515	-8.5%	-4.7%	-3.8%
WW	483	514	-6.0%	-4.0%	-2.0%	960	1,026	-6.4%	-4.5%	-1.9%
<u>INFECTION PREVENTION/OTHER</u>										
US	95	99	-4.0%	-4.0%	-	180	215	-16.3%	-16.3%	-
Intl	139	131	6.1%	12.3%	-6.2%	266	259	2.7%	8.2%	-5.5%
WW	234	230	1.7%	5.2%	-3.5%	446	474	-5.9%	-2.9%	-3.0%
<u>ORTHOPAEDICS</u>										
US	1,274	873	45.9%	45.9%	-	2,535	1,656	53.1%	53.1%	-
Intl	1,111	755	47.2%	52.4%	-5.2%	2,235	1,465	52.6%	56.3%	-3.7%
WW	2,385	1,628	46.5%	48.9%	-2.4%	4,770	3,121	52.8%	54.5%	-1.7%
<u>SPECIALTY SURGERY</u>										
US	331	336	-1.5%	-1.5%	-	650	663	-2.0%	-2.0%	-
Intl	325	310	4.8%	7.5%	-2.7%	633	611	3.6%	6.2%	-2.6%
WW	656	646	1.5%	2.8%	-1.3%	1,283	1,274	0.7%	1.9%	-1.2%
<u>SURGICAL CARE</u>										
US	577	602	-4.2%	-4.2%	-	1,108	1,195	-7.3%	-7.3%	-
Intl	1,011	1,038	-2.6%	0.6%	-3.2%	1,988	2,070	-4.0%	-1.0%	-3.0%
WW	1,588	1,640	-3.2%	-1.2%	-2.0%	3,096	3,265	-5.2%	-3.3%	-1.9%
<u>VISION CARE</u>										
US	262	253	3.6%	3.6%	-	543	530	2.5%	2.5%	-
Intl	468	477	-1.9%	6.4%	-8.3%	927	957	-3.1%	4.1%	-7.2%
WW	730	730	0.0%	5.4%	-5.4%	1,470	1,487	-1.1%	3.5%	-4.6%
<b>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</b>										
US	3,243	2,953	9.8%	9.8%	-	6,449	5,830	10.6%	10.6%	-
Intl	3,951	3,612	9.4%	13.7%	-4.3%	7,807	7,146	9.2%	12.9%	-3.7%
WW	\$ 7,194	6,565	9.6%	12.0%	-2.4%	\$ 14,256	12,976	9.9%	12.0%	-2.1%

\* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Nutritionals now reflected in Wound Care/Other, previously reported in OTC/Nutritionals

(4) Prior year amounts have been reclassified to conform to current year product disclosure

(5) Reported as U.S. sales